• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BARD PERIPHERAL VASCULAR, INC. IMPRA EPTFE VASCULAR GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BARD PERIPHERAL VASCULAR, INC. IMPRA EPTFE VASCULAR GRAFT Back to Search Results
Model Number 40S06
Device Problem Obstruction of Flow (2423)
Patient Problem Thrombosis/Thrombus (4440)
Event Date 08/06/2020
Event Type  Injury  
Manufacturer Narrative
As the lot number for the device was provided, a manufacturing review will be performed.The sample was not returned to the manufacturer for inspection/evaluation.Therefore, the investigation of the reported event is inconclusive.Based upon the available information, the definitive root cause for this event is unknown.The instructions for use (ifu) is adequate for the reported device/patient code(s) and provides general instructions for use, as well as warnings, precautions and potential complications associated with the device.Upon receipt of new or additional information, a follow-up report will be submitted as applicable.(expiry date: 01/2021).
 
Event Description
It was reported through a clinical trial that approximately 1225 days post study conduit placement, there was thrombosis of vascular access.Approximately 1261 days post study conduit placement, the patient was hospitalized due to thrombosis of vascular access.Approximately 1262 days post study conduit placement, the subject underwent a thrombectomy and the event was considered resolved.The same day, the patient experienced a second thrombosis of vascular access which prolonged hospitalization.Approximately 1265 days post study conduit placement, the patient underwent a repeat thrombectomy with angioplasty.The thrombosis was resolved the same day and the patient was discharged the following day post uneventful dialysis.The current status of the patient was not provided.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMPRA EPTFE VASCULAR GRAFT
Type of Device
EPTFE VASCULAR GRAFT
Manufacturer (Section D)
BARD PERIPHERAL VASCULAR, INC.
1625 w 3rd st.
tempe AZ 85281
Manufacturer (Section G)
BARD PERIPHERAL VASCULAR, INC.
1625 w 3rd st.
tempe AZ 85281
Manufacturer Contact
judy ludwig
800 w. rio salado pkwy
tempe, AZ 85281
4803032689
MDR Report Key11018518
MDR Text Key221744143
Report Number2020394-2020-20845
Device Sequence Number1
Product Code DSY
UDI-Device Identifier00801741021831
UDI-Public(01)00801741021831
Combination Product (y/n)N
Reporter Country CodePL
PMA/PMN Number
K004011
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,other,study
Reporter Occupation Physician
Type of Report Initial
Report Date 11/20/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model Number40S06
Device Catalogue Number40S06
Device Lot NumberVTAP0037
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 11/19/2020
Initial Date FDA Received12/16/2020
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
ALLOPURINOL, BISOPROLOL FUMARATE; FUROSEMIDE, CALCIUM CARBONATE; INSULIN HUMAN, AND ACETYLSALICYLIC ACID; PANTOPRAZOLE, PERINDOPRIL ARGININE, ALFACALCIDOL
Patient Outcome(s) Other;
Patient Age74 YR
Patient Weight120
-
-